Business
If only Ellume was an ASX share! Why it’s making big news today
For an unlisted company, Ellume certainly knows how to keep ASX investors talking. The Brisbane-based health company also made news last year. This was due to its announcement that the United States Food and Drug Administration (FDA) had endorsed one of its products.
As we discussed at the time, Ellume specialises in rapid diagnostic technology. The company had developed a rapid test for the COVID-19 infection. The test only costs around US$30. It can reportedly detect traces of coronavirus in as little as 15 minutes with a 94% sensitivity in detecting infection.
Following that endorsement from the FDA, Ellume ramped up plans to send more than 100,000 of its tests to the US. At the time, Ellume planned on delivering more than 5…
-
Noosa News18 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference
-
Business21 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business18 hours agoDicker Data rides the AI trend to double digit growth
-
Business21 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy